24HrDoc: What the FDA Letter Means for What You Pay

This letter is to advise you that the United States Food and Drug Administration (FDA) reviewed your website content at the internet address https://www.24hrdoc.com, in December 2025, and has observed that your website offers compounded drug products, including semaglutide and tirzepatide drug products.

1. 1

   “The compounded semaglutide and tirzepatide products displayed on your website identify “24HrDoc” on the pictured label, suggesting 24HrDoc is the compounder of those drugs when in fact it is not.”

2. 2

   “Additionally, the following claims concerning compounded semaglutide and tirzepatide products appear on your website: “Same ingredients as: Ozempic and Wegovy” “Same ingredients as: Mounjaro and Zepbound””

3. 3

   “Compounded drug products are not FDA-approved. Your claims imply that your products have been FDA-approved or otherwise evaluated for safety and effectiveness when they have not.”

1. 1

   Letter issued

   February 2026

2. 2

   15-working-day response window

   FDA gives the company 15 working days to respond in writing.

3. 3

   Close-out, if issued

   FDA may post one once it is satisfied the cited issues have been corrected.

www.24hrdoc.com returned a live storefront on 2026-08-09 titled "24/7 Virtual Healthcare: Affordable Online Doctor Visits - 24hrdoc", with visits priced from $39.99 and per-product monthly pricing published on the home page, including a weight-loss product shown at a "First month" price of $149 against $249/month.

Read the two quoted lines again and notice what is missing: the word "active". "Same ingredients as: Ozempic and Wegovy" is a claim about the whole formulation — everything in the vial — not about the one molecule the products share. That is a bigger promise than the sellers around it made, and it is the reason this letter exists. It also happens to be the promise a price comparison rests on, because if two products are identical in every respect then the only remaining variable is what you pay. FDA's answer does not touch the drug: it says a compounded product is not FDA-approved and this wording implied it had been evaluated when it had not. So the letter leaves the price alone and takes away the premise. If you are weighing a compounded course against a branded one, the difference between them is not nothing, and "same ingredients" was not a sound basis for treating it as nothing. This is a general-practice telehealth service, and the same reasoning applies to every product on the page, not only the GLP-1s.

As of August 2026, FDA’s public tracking for this letter does not show a logged company response. Companies are not required to make a response public, and FDA does not always update this field promptly — this is not evidence 24HrDoc failed to respond.